About HIBio
HIBio is a Healthcare company based in Foshan (China) founded in 2021 by Travis Murdoch, and was acquired by Biogen in May 2024. Precision medicines for autoimmune and inflammatory diseases are developed. HIBio has raised $215 million across 2 funding rounds from investors including Biogen, Arch Venture Partners and Arkin. Its chief executive, as recorded, is Travis Murdoch. HIBio offers products and services including Neurological Therapies. Its focus areas include Life Sciences, Immunology, Drugs and Diversified.
Company details
HIBio was founded in 2021 in Foshan, China, by Travis Murdoch, who serves as CEO. Operations focus on the biotechnology sector, where precision medicines targeting autoimmune and inflammatory diseases are developed. Research and development activities are centered in China, with an emphasis on therapeutic innovations for unmet medical needs in immunology. The companys domain, hibio.com, supports its ongoing efforts in this field.
Products & Services of HIBio
HIBio offers a comprehensive portfolio of products and services, including Neurological Therapies.
Treatments for neurological disorders like Alzheimer's
Funding Insights of HIBio
HIBio has successfully raised a total of $215M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $95 million completed in January 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $215M
- Total Rounds 2
- Last Round Series B — $95M
- First Round $120M
(Nov 2022)
- Investors Count 6
All 2 funding rounds of HIBio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2024 | $95M | Series B | – | Alpha Wave Global | |
| Nov 2022 | $120M | Series B | – | Arch Venture Partners, Monograph | – |
7 investors in total: 7 institutional.
Investors in HIBio
HIBio has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Biogen, Arch Venture Partners and Arkin.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm focused on growth-stage companies | alphawaveglobal.com | New York, United States | ||
Private investment firm focused on multiple sectors | vikingglobal.com | Greenwich, United States | ||
Jeito Capital is focused on financing medical innovation globally. | jeito.life | Paris, France | ||
Venture capital firm focused on life science companies | 1986 | archventure.com | Chicago, United States | |
Monograph Capital is focused on life sciences investment. | monograph.bio | |||
IT operations monitoring is provided for software-defined data centers. | 2013 | arkin.net | Santa Clara, United States | |
Therapies for neurodegenerative and immunology disorders are developed. | 1978 | biogen.com | Cambridge, United States |
Investor details for HIBio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of HIBio
7 people are tracked at HIBio (3 in leadership, 4 in team).
| Name | Role | Group |
|---|---|---|
Travis Murdoch | Founder & CEO | Leadership |
Teresita Arenzana Delfino | Associate Director | Translational Sciences | Leadership |
Jen Wilson | Sr. Director | Leadership |
Hannah Lock | Senior Associate Scientist, Immunology | Team |
Matthew Albert, MD, PhD | Chair, Scientific Advisory Board | Team |
Guorui Xie | Senior Scientist | Biomarker/translational Immunology | Hi-bio | Team |
Jonathan Carroll | Senior Research Software Engineer | Team |
Complete people profiles for HIBio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of HIBio
4 dated milestones of HIBio across 3 years, from founding to its latest funding, stage changes and deals.
- Founded HIBio is founded.
- Funding First funding round of $120.0M.
- Funding Latest funding round, Series B, of $95.0M.
- Exit Acquired by Biogen.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Hibio
Complete news archive for HIBio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about HIBio
HIBio was founded in 2021 and raised its 1st funding round 1 year after it was founded.
HIBio is headquartered in Foshan, China. It is registered at Foshan, Guangdong, China.
Travis Murdoch is the CEO of HIBio, as recorded in our data. They have also founded this company.
HIBio is a funded company, having raised a total of $215M across 2 funding rounds to date. The company's 1st funding round was a Series B of $120M, raised on Nov 2022.
HIBio was founded in 2021 in Foshan, China, by Travis Murdoch, who serves as CEO. Operations focus on the biotechnology sector, where precision medicines targeting autoimmune and inflammatory diseases are developed. Research and development activities are centered in China, with an emphasis on therapeutic innovations for unmet medical needs in immunology. The companys domain, hibio.com, supports its ongoing efforts in this field.
HIBio offers Neurological Therapies.
HIBio has 7 investors. Key investors include Biogen, Arch Venture Partners, Arkin, Alpha Wave Global, and Viking Global Investors.
Yes. HIBio was acquired by Biogen in May 2024.